Unmixed Infliximab Biosimilar from Japan
Infliximab biosimilar is a monoclonal antibody binding TNF-alpha, used for inflammatory conditions like rheumatoid arthritis. HTS 3002.13.0090 covers it as an unmixed, biotech-derived immunological product not in retail form. It qualifies per chapter notes as a protein regulating immunological processes.
Duty Rate — Japan → United States
0%
Rate breakdown
9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Import Tips
• Provide biotech manufacturing details and sequence data to distinguish from chemical synthetics under Chapter 29
• Comply with CBP biotech import requirements, including advance notice for high-value shipments over $10,000
• Label clearly as 'unmixed' to prevent reclassification; dilution in water still counts as unmixed per chapter notes